GlassScriptPhysician profile
Jason Adrian Adler
NPI 1194252148
$1,786.65
in general payments reported to CMS, 2019-2025
30 companies · $353 in 2025
The $353 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $172 · 2023: $547 · 2024: $714 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.64 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $236.44 | 2023-2024 | |
| Blueprint Medicines Corporation | $113.58 | 2023-2025 | Ayvakit |
| Genzyme Corporation | $99.28 | 2022-2025 | |
| Celgene Corporation | $91.55 | 2022-2025 | Reblozyl |
| Aveo Pharmaceuticals, INC. | $89.99 | 2024 | |
| Genmab U.S., INC. | $87.28 | 2023-2024 | Epkinly, Tivdak |
| Takeda Pharmaceuticals U.S.A., INC. | $86.92 | 2023-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Incyte Corporation | $85.05 | 2022-2024 | Jakafi |
| Daiichi Sankyo INC. | $83.40 | 2024-2025 | Enhertu |
| Seagen INC. | $75.83 | 2022-2023 | Tukysa |
| Astrazeneca Pharmaceuticals LP | $74.06 | 2023-2025 | Lynparza, Calquence, Tagrisso |
| Merck Sharp & Dohme LLC | $72.21 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $71.87 | 2024-2025 | |
| Pfizer INC. | $71.34 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $56.69 | 2023-2024 | Ultomiris |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.10 | 2022-2023 | Xgeva, Vectibix, Nplate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.98 | 2022-2023 | Gilotrif |
| Genentech USA, INC. | $37.64 | 2023-2025 | Tecentriq, Alecensa |
| Eisai INC. | $34.93 | 2023-2024 | |
| Array Biopharma INC | $28.54 | 2022-2024 | Mektovi, Lorbrena, Xalkori |
| Lilly USA, LLC | $26.60 | 2025 | Jaypirca, Verzenio |
| Pharmacyclics LLC, An Abbvie Company | $22.50 | 2022 | |
| Sobi, INC | $22.02 | 2024 | |
| Jazz Pharmaceuticals INC. | $21.79 | 2024 | |
| Beone Medicines USA, INC. | $20.03 | 2025 | Tevimbra |
| Gilead Sciences, INC. | $19.98 | 2024 | |
| Morphosys, US INC. | $17.26 | 2023 | Monjuvi |
| Janssen Pharmaceuticals, INC | $16.09 | 2022 | |
| Rigel Pharmaceuticals, INC. | $14.84 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Bayer Healthcare Pharmaceuticals INC. | $12.86 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Adler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.